دورية أكاديمية
Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?
| العنوان: | Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads? |
|---|---|
| المؤلفون: | Jyani G; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India., Gupta N; Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India. Electronic address: nidhiguptaonco@gmail.com. |
| المصدر: | Value in health regional issues [Value Health Reg Issues] 2024 Jul; Vol. 42, pp. 100991. Date of Electronic Publication: 2024 May 08. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101592642 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-1102 (Electronic) Linking ISSN: 22121099 NLM ISO Abbreviation: Value Health Reg Issues Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York : Elsevier |
| مواضيع طبية MeSH: | Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/economics , Adenine*/analogs & derivatives , Adenine*/therapeutic use , Adenine*/economics , Cost-Benefit Analysis*/methods , Piperidines*/therapeutic use , Piperidines*/economics , Pyrimidines*/economics , Pyrimidines*/therapeutic use , Pyrazoles*/economics , Pyrazoles*/therapeutic use, Humans ; India/epidemiology ; Antineoplastic Agents/economics ; Antineoplastic Agents/therapeutic use |
| مستخلص: | In recent years, newer drugs, such as ibrutinib, have shown promising improvements in the survival of patients with chronic lymphocytic leukemia (CLL). Despite their effectiveness, concerns about their cost have arisen, prompting the need for an evaluation of their cost-effectiveness. However, recent assessments of ibrutinib's cost-effectiveness for treating CLL in India reveal divergent conclusions. The discord centers on divergent cost-effectiveness thresholds, comparator regimens, cost calculations, and outcome valuation approaches. Such discrepancies affect public health decisions and patient care. The recommendation calls for adherence to methodological guidelines by future studies, fostering consistent findings to empower policy makers and clinicians in leveraging economic evidence for informed decision making in CLL treatment strategies. Competing Interests: Author Disclosures Author disclosure forms can be accessed below in the Supplemental Material section. (Copyright © 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: India; chronic lymphocytic leukemia; cost of treatment; cost-effectiveness; economic evaluation |
| المشرفين على المادة: | 1X70OSD4VX (ibrutinib) JAC85A2161 (Adenine) 0 (Piperidines) 0 (Pyrimidines) 0 (Pyrazoles) 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20240509 Date Completed: 20240629 Latest Revision: 20240629 |
| رمز التحديث: | 20240630 |
| DOI: | 10.1016/j.vhri.2024.100991 |
| PMID: | 38723366 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2212-1102 |
|---|---|
| DOI: | 10.1016/j.vhri.2024.100991 |